Clinicel study on treatment of advanced primary liver cancer by Yanshu injection combining with chemotherapy.
- Author:
Cheng-Nong GUAN
1
;
Liang-Zhen CAI
;
Li-Qun YUE
;
Ying ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Agents, Phytogenic; administration & dosage; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Drug Therapy, Combination; Drugs, Chinese Herbal; administration & dosage; isolation & purification; therapeutic use; Female; Humans; Injections, Intravenous; Liver Neoplasms; drug therapy; pathology; Male; Middle Aged; Neoplasm Staging; Phytotherapy; Plants, Medicinal; chemistry; Quality of Life; Sophora; chemistry; Survival Rate
- From: China Journal of Chinese Materia Medica 2006;31(6):510-512
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effects of Yanshu injection on the combined treatment in the advanced primary liver cancer.
METHODEighty-five cases of advanced primary liver cancer were treated with Yanshu injection combining with chemotherapy or only chemotherapy. The curative effects, pain genesic rate, one year survival rate, survival quality of life and cell immune functions were observed.
RESULTThe remission rate and one year survival rate of the trial group were 60.5% and 51.2%, respectively, and were significantly higher than those (45.2% and 40.5%) of the control group (P < 0.05). The pain relief rate of the trial group was significantly higher than that of the control group (P < 0.05). The improvement of the quality of life was higher than that of the contral group (P < 0.01). The ability of the T-cell subgroup and NK-cell of the trail group were significantly difference between pre-and post-treatment (P < 0.01 or 0.05); however, that of the control group was no obviously change.
CONCLUSIONYanshu injection combination with chemotherapy can raise the curative effect, one year survival rate and cellular immune function, reduce pain genesic rate and toxicity of chemotherapy, and improve the quality of life of the patients with advanced primary liver cancer, which is worthy to be recommended for clinical application.
